Publication

Article

Lung Cancer Heroes®

CURE® Lung Cancer Heroes® 2021 Essay Book
Volume2

Guiding the Way for Patients With Lung Cancer: 'He Is my Hero'

Author(s):

Timothy J. Barry

A lung cancer survivor shares a heartfelt tribute to Dr. Abraham Chachoua, who changed his life.

Dr. Abraham Chachoua

From left: Timothy J. Barry and Dr. Abraham Chachoua. Photo by Claudio Papapietro.

I was diagnosed with lung cancer in 2011. It didn’t look good. Dr. Abraham Chachoua kept me alive long enough to get me into the 2015 drug trial for Opdivo (nivolumab) at Memorial Sloan Kettering Cancer Center. I had such bad side effects that I didn’t finish the trial. But it worked.

My last CT scan showed no cancer. He is my hero.

Dr. Abraham Chachoua at the PER® 14th Annual New York Lung Cancers Symposium

Dr. Abraham Chachoua at the PER® 14th Annual New York Lung Cancers Symposium. Photo by Michel Nafziger.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Download Issue PDF
Articles in this issue
A Deep Dedication to Improving Outcomes for Patients With Lung Cancer
A Deep Dedication to Improving Outcomes for Patients With Lung Cancer
Breaking the Stigma: Anyone Can Get Lung Cancer
Breaking the Stigma: Anyone Can Get Lung Cancer
The Lung Cancer Advocate Who Is a Friend to All
The Lung Cancer Advocate Who Is a Friend to All
Rock Star Lung Cancer Supporter and Advocate
Rock Star Lung Cancer Supporter and Advocate
My Wife’s Oncologist Is a Hero
My Wife’s Oncologist Is a Hero
A Champion for Expanding Access to Lung Cancer Breakthroughs
A Champion for Expanding Access to Lung Cancer Breakthroughs
Lung Cancer Research Advocacy Driven by Heart
Lung Cancer Research Advocacy Driven by Heart
When a Lung Cancer Diagnosis Brings About a New Mission
When a Lung Cancer Diagnosis Brings About a New Mission
Lung Cancer Hero Implements ‘Tar Wars’ School Initiative Program
Lung Cancer Hero Implements ‘Tar Wars’ School Initiative Program
Making Cancer Medicine More Compassionate
Making Cancer Medicine More Compassionate
A Physician-Scientist With a Huge Heart for Patients With Lung Cancer
A Physician-Scientist With a Huge Heart for Patients With Lung Cancer
My Dear Friend and Cancer ‘Warrior’ Refuses to Fold
My Dear Friend and Cancer ‘Warrior’ Refuses to Fold
The Superhero Oncologist Who Saved My Friend From Cancer
The Superhero Oncologist Who Saved My Friend From Cancer
When an Unexpected Cancer Association Leads to a Lifelong Connection
When an Unexpected Cancer Association Leads to a Lifelong Connection
'All Roads Lead to Roman': A Hero Among Lung Cancer Doctors
'All Roads Lead to Roman': A Hero Among Lung Cancer Doctors
Related Videos
Image of a man in a suit.
Image of man with black hair.
Image of man with gray hair.
Image of Dr. Minesh Mehta at ASCO 2024.
Related Content
"FDA" text.
Published: December 18th 2024 | Updated: December 19th 2024

FDA Approves Ensacove for ALK-Positive NSCLC

Alex Biese
The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
"FDA" text.
December 5th 2024

FDA OKs Imfinzi for Limited-Stage Small Cell Lung Cancer

Darlene Dobkowski, MA
Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease progression after chemotherapy and radiation.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of FDA Breakthrough Therapy Designation on a gold background.
December 3rd 2024

FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC

Alex Biese
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic nonsquamous NSCLC with EGFR mutations.
Illustration of a person holding a magnifying glass next to paperwork and pills.
December 3rd 2024

Nemvaleukin Shows Manageable Safety Profile in Advanced Solid Tumors

Ashley Chan
In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.